The foreign affiliate of the major pharmaceutical company behind OxyContin, a controversial drug blamed in part for unleashing America’s opioid epidemic, is now expanding to offer an overdose cure. Mundipharma's antidote, a naloxone nasal spray called Nyxoid, recently was approved in New Zealand, Europe and Australia. Patrice Grand, a spokesman for Mundipharma Europe, said in a statement that heroin was the leading cause of overdose death in European countries and nasal naloxone represented an important treatment option. But, in Australia, Mundipharma embarked on an effort to promote naloxone that was sweeping and effective. The U.S. opioid epidemic has killed over 400,000 people and counting.

Source: Fox News December 15, 2019 21:33 UTC